1. An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer.
- Author
-
Takashima T, Nishimura S, Kawajiri H, Mizuyama Y, Nishimori T, Yamagata S, Tokunaga S, Tezuka K, Tei S, Sunami T, Ikeda K, Ogawa Y, Kashiwagi S, Noda S, Onoda N, Ishikawa T, Kudoh S, Takada M, Hirakawa K, and Ohira M
- Subjects
- Adult, Aged, Breast Neoplasms metabolism, Breast Neoplasms pathology, Female, Fluorouracil administration & dosage, Follow-Up Studies, Furans administration & dosage, Humans, Ketones administration & dosage, Middle Aged, Neoplasm Recurrence, Local metabolism, Neoplasm Recurrence, Local pathology, Prognosis, Retreatment, Survival Rate, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor metabolism, Breast Neoplasms drug therapy, Neoplasm Recurrence, Local drug therapy, Receptor, ErbB-2 metabolism
- Abstract
Background/aim: In our previous study, first-line eribulin (ERI) showed 25 weeks of progression-free survival (PFS). This study investigated the efficacy and safety of ERI re-administration in metastatic breast cancer (MBC) patients., Patients and Methods: HER2-negative MBC patients who had never received chemotherapy for MBC received first-line ERI for 18 weeks if they did not have disease progression, and then one cycle of S-1 before ERI re-administration., Results: Twelve patients received ERI re-administration. The PFS of re-administered ERI was 13 weeks. Total duration of ERI use was 30 weeks. The incidence and severity of adverse events were consistent with previous reports., Conclusion: In the first-line setting, the total PFS of eribulin was extended by S-1 administration before disease progression, compared with that of our previous report., (Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF